Dibotermin alfa

Summary

Dibotermin alfa is a recombinant human bone morphogenetic protein‑2 (rhBMP‑2) approved for surgical use to promote bone healing. Delivered locally on an absorbable collagen sponge, it is employed in orthopaedic procedures such as treatment of open tibial fractures and lumbar spinal fusion, where it aims to accelerate bone formation and reduce the need for additional surgeries.

Mechanism of Action

Dibotermin alfa mimics the natural BMP‑2 growth factor, binding to type I and type II BMP receptors on mesenchymal progenitor cells. This triggers SMAD‑dependent signalling that drives osteoblast differentiation, extracellular matrix production and mineralisation. The cascade also modulates antagonists such as Noggin and influences osteoclast activity through RANKL pathways, collectively enhancing new bone formation at the implantation site.

What the Research Shows

A prospective randomised trial in 450 patients with open tibial fractures showed that a 12 mg dose (1.5 mg/mL) of dibotermin alfa reduced secondary interventions by 44 % and accelerated fracture and wound healing compared with standard care. Economic evaluations in the United Kingdom using pooled data from multiple spinal fusion trials reported incremental quality‑adjusted life‑years (0.055 QALY) at an additional cost of £737, yielding an ICER of £13,523 and indicating cost‑effectiveness versus autologous iliac crest graft. A later model for lumbar disc disease predicted modest cost savings (£192 per patient) and a small QALY gain (0.0114). Gene‑expression work in human osteoblasts identified three responder phenotypes, suggesting that up to one‑third of patients may not benefit due to inhibitory pathways. A veterinary report noted regulatory approval for small‑animal use in 2013.

Reported Benefits

Clinical data demonstrate faster bone union, fewer secondary surgeries and lower infection rates in open tibial fractures. Economic analyses suggest dibotermin alfa can be a cost‑effective alternative to autologous bone graft in lumbar fusion, providing modest QALY improvements and potential cost savings. The protein’s ability to stimulate osteoblast activity may also reduce the morbidity associated with harvesting autograft tissue.

Limitations of the Evidence

Evidence is confined to specific orthopaedic indications; long‑term outcomes beyond 12 months are not reported. Gene‑expression studies indicate that roughly 30 % of patients may not respond, highlighting variability in efficacy. Economic models rely on assumptions about resource use and quality‑of‑life gains, and results may not generalise to other health systems. Safety data are limited to the trial’s observation of no major adverse events, without detailed reporting of known BMP‑2 risks such as ectopic bone formation.

Safety Considerations

The tibial fracture trial reported the rhBMP‑2 implant to be safe, with fewer infections in the high‑dose group. No serious adverse events were highlighted in the abstracts, but typical BMP‑2 concerns (e.g., ectopic ossification, inflammatory reactions) are not addressed in the available literature, so cautious monitoring is advised when used surgically. Veterinary approval suggests species‑specific safety evaluation, but human safety data remain limited to the reported trial.

How It Is Administered

Dibotermin alfa is supplied on an absorbable collagen sponge that is implanted locally at the surgical site, often over an intramedullary nail in fracture fixation or within the disc space during spinal fusion. Administration is performed during the operative procedure via local implantation or intra‑osseous placement; no systemic dosing is used.

Routes of Administration

Goals & Uses

• Tibial shaft fracture repairOrthopedic / TraumaHigh
• Alveolar ridge augmentationDental SurgeryModerate
• Tibial non‑union repairOrthopedic SurgeryHigh
• Sinus augmentation and alveolar ridge augmentationDental / Oral SurgeryModerate
• Cervical spinal fusionOrthopedic / SpineLow
• Posterolateral lumbar spinal fusionOrthopedic / SpineModerate
• Lumbar spinal fusion (ALIF)Orthopedic / SpineHigh
• Spinal fusionOrthopedic SurgeryHigh

Contraindications

• Active malignancy at implantation siteOncologyHigh
• Cervical spine implantationAnatomicalHigh
• Known hypersensitivity to BMP‑2 or carrier matrixAllergyHigh
• Skeletally immature patientsPediatricHigh
• Known or suspected malignancy at or near implant siteOncologicHigh
• Infection at surgical siteInfectionModerate
• Hypersensitivity to rhBMP-2 or bovine collagenAllergicHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Active infection at implant siteInfectiousHigh

Adverse Effects

• Retrograde ejaculationReproductiveUncommon
• Swelling and seromaLocal/InflammatoryCommon
• Immunogenic reactionSystemicUncommon
• Ectopic bone formationMusculoskeletalCommon
• Implant failure / subsidenceMechanicalUncommon
• Cancer risk (potential)OncologicRare
• Osteolysis / radiolucencyMusculoskeletalCommon
• Inflammatory swelling/seromaLocalCommon

Drug Interactions

• Non‑steroidal anti‑inflammatory drugs (NSAIDs)Moderate
• NSAIDsLowMay increase renal risk in susceptible patients
• CorticosteroidsModerate

Population Constraints

• Pediatric patients (skeletally immature)AgeAbsolute
• Pediatric patientsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Patients with active or prior malignancyOncologicRelative
• Pregnant womenReproductiveAbsolute
• Patients with autoimmune or inflammatory conditionsImmunologicRelative

Regulatory Status

• European UnionApprovedApproved: Spinal fusion, Long‑bone fracture repairAuthorized under the name OP‑1; similar indication restrictions as US.
• United StatesApprovedApproved: Anterior lumbar interbody fusion, Open tibial shaft fracture non‑unionMarketed as Infuse Bone Graft; use limited to FDA‑cleared indications.
• United KingdomApprovedApproved: Single-level anterior lumbar interbody fusionApproved as InductOs; NICE has issued guidance on use with conditions including specialist oversight and informed consent regarding cancer risk uncertainty.

Approved in the US (Infuse Bone Graft) for specific lumbar spinal fusion and tibial fracture applications; EU approval for similar orthopedic indications. Use outside approved sites is off‑label.

Evidence & Sources

• Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients
  Journal ArticleModerateGovender S, et al.2002-01-01T00:00:00.000000Z
• Gateways to clinical trials
  Journal ArticleModerateBayés M, Rabasseda X, Prous JR2003-01-01T00:00:00.000000Z
• Is dibotermin alfa a cost-effective substitute for autologous iliac crest bone graft in single level lumbar interbody spine fusion?
  Journal ArticleHighSvedbom A, et al.2015-01-01T00:00:00.000000Z
• Cost-effectiveness of 4 mg dibotermin alfa/absorbable collagen sponge versus iliac crest bone graft for lumbar degenerative disc disease in the United Kingdom
  Journal ArticleHighCumming D, et al.2022-01-01T00:00:00.000000Z
• [New drugs for small animals in 2013]
  Journal ArticleLowEmmerich IU2014-01-01T00:00:00.000000Z
• Distinct Gene Expression Patterns Defining Human Osteoblasts' Response to BMP2 Treatment: Is the Therapeutic Success All a Matter of Timing?
  Journal ArticleLowEhnert S, et al.2016-01-01T00:00:00.000000Z

Frequently Asked Questions